A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate

Gynecologic Oncology

Volumn 101, Issue 3, 2006, Pages 545-547

  Salvatierra, Alejandro ^a   Tarrats, Antonio ^b   Gomez, Carmen ^b   Sastre, Josep Maria ^b   Balaña, Carmen ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

c kit; Endometrial stromal sarcoma; Imatinib Mesylate

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ADULT; ANAMNESIS; ANEMIA; ARTICLE; CASE REPORT; DISEASE COURSE; EDEMA; ENDOMETRIUM SARCOMA; FEMALE; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SARCOMA, ENDOMETRIAL STROMAL; VAGINAL NEOPLASMS;

EID: 33646739922     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.01.024     Document Type: Article

References (9)

1. Olah K.S., Dunn J.A., and Gee H. Leymiosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: results of a retrospective study of 423 cases of uterine sarcoma. Br. J. Obstet. Gynaecol. 99 (1992) 590-594
2. Piver M.S., Rutledge F.N., Copeland L., Webster K., Blumenson L., and Suh O. Uterine endolymphatic stromal myosis: a collaborative study. Obstet. Gynecol. 64 (1995) 173
3. Berchuck A., Rubin S.C., Hoskins W.J., Saigo P.E., Pierce V.K., and Lewis J.L. Treatment of endometrial stromal tumors. Gynecol. Oncol. 36 (1990) 60-65
4. Chang K., Crabtree G., Lim-Tan S., Kempson R., and Hendrickson M. Primary uterine endometrial stromal neoplasm. Am. J. Surg. Pathol. 14 (1990) 415-438
5. Tsukamoto N., Kamura T., and Mutsukuma K. Endolymphatic stromal myosis: a case with positive estrogen and progesterone receptors and good response to progestins. Gynecol. Oncol. 20 (1985) 120-128
6. Leath C.A., Straughn J.M., Conner M.G., Barnes M.N., Partridge E.E., and Huh W.K. Immunohistochemical evaluation of the c-kit proto-oncogene sarcomas of the uterus: a case series. J. Reprod. Med. 49 (2004) 71-75
7. Heinrich M.C., Corless C.L., Dimetri G.D., et al. Kinase mutations and Imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21 (2003) 4342-4349
8. Rushing S., Shajahan S., Chendil D., Wilder J.L., Pulliam J., Lee E.U., et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon or 17 of c-KIT. Gynecol. Oncol. 91 (2003) 9-14
9. Caudell J.J., Deavers M.T., Slomovitz B.M., Lu K.H., Broaddus R.R., Gershenson D.M., et al. Imatinib Mesylate (Gleevec)-targeted kinases are expressed in uterine sarcomas. Appl. Immnunohistochem. Mol. Morphol. 13 (2005) 167-170